HomeBlogPeptide HPLC Certificate Explained
Quality & Handling

Peptide HPLC Certificate Explained — What UAE Researchers Should Check on Every COA

14 June 202611 min readREVIVE LAB UAE Research Desk
Peptide HPLC certificate of analysis UAE research

A peptide certificate of analysis (COA) is the single most important piece of paper in research-grade peptide purchasing — and the single most commonly faked. Generic or templated COAs are the norm in the grey market; lot-specific, instrument-traceable COAs are the exception. This guide walks what HPLC actually measures, why identity confirmation requires mass spectrometry separately from purity, and what UAE peptide researchers should actually check before reconstituting any vial — whether the supplier is REVIVE LAB or anyone else.

The COA is your dose-response data integrity check. If the peptide identity or purity differs from what's printed, every result generated downstream is confounded. There is no recovery from a bad COA except by re-testing — at independent lab cost — in your own facility.

1. What HPLC actually is and what it measures

High Performance Liquid Chromatography (HPLC) is the standard analytical method for assessing peptide purity. A small sample of the peptide is dissolved, pushed through a chromatographic column under high pressure, and separated by interaction with the column's stationary phase. Different molecules travel through at different speeds and exit at different times. A UV detector at the column outlet records absorbance vs time — the resulting plot is the chromatogram.

Each peak in the chromatogram represents a distinct molecular species. The target peptide is the dominant peak. Smaller peaks are impurities — typically synthesis byproducts: truncated sequences (a peptide bond didn't form), deletion sequences (an amino acid was missed), oxidation products (methionine residues commonly oxidise), aggregation products.

HPLC purity = area of the target peptide peak / total chromatogram area, expressed as percentage. 98% HPLC purity means 98% of the absorbance area is the target peak. The remaining 2% is everything else.

2. Why HPLC alone is not enough

HPLC tells you the sample is mostly one molecule. It does not tell you which molecule. The peak with the highest area is the dominant species, but the chromatogram alone cannot confirm it's the molecule you ordered. A peptide can show 99% HPLC purity and be the wrong sequence — a different peptide of similar length and chemistry could chromatograph as a clean single peak.

This is why mass spectrometry is the separate identity-confirmation step. MS measures the molecular weight of the dominant peak directly. The theoretical molecular weight of any peptide is calculable from its sequence: sum of amino-acid residue masses + 18 (for the terminal water). MS-measured mass that matches theoretical mass (within ±0.5 Da for short peptides, ±1 Da for longer) confirms identity.

MethodWhat it measuresWhat it doesn't
HPLCPurity (% of dominant peak)Identity of the peak
Mass spectrometry (MS)Molecular weight of dominant species → identityQuantitative purity
MALDI-TOF MSIdentity for medium/large peptidesTrace impurity detection
ESI-MS (LC-MS combined)Identity + purity in one chromatogramHigher equipment cost

A proper research-peptide COA shows both HPLC purity AND MS identity confirmation. Either one alone is insufficient.

3. What a real lot-specific COA looks like

A lot-specific peptide COA contains specific, instrument-traceable elements. The standard fields:

Templated COAs that have only a peptide name + "98%" with no chromatogram, no MS data, and no lot number are not COAs. They're marketing claims printed on letterhead.

4. Reading the HPLC chromatogram — what to actually look at

The chromatogram is a plot with time on the X axis (typically 0-30 minutes) and UV absorbance on the Y axis. Each peak is a separate molecule. What to check:

5. Reading the MS spectrum — what to actually look at

The mass spectrum is a plot with mass-to-charge (m/z) on the X axis and intensity on the Y axis. The main thing to verify is that the detected m/z value (with charge state corrected) matches the theoretical molecular weight of the peptide:

Worked example — BPC-157. Sequence: GEPPPGKPADDAGLV. Theoretical MW: 1419.5 Da. A correct MS spectrum should show a dominant peak at m/z ~1420.5 (+1 charge state) or ~710.8 (+2 charge state). Anything else suggests the wrong peptide.

6. Common red flags on peptide COAs

7. The compounded GLP-1 grey market case study

The 2024-2026 compounded GLP-1 supply explosion in the UAE and globally has produced a specific COA-quality problem: many compounded semaglutide and tirzepatide products are reconstituted at non-stated concentrations, with COAs that show purity but not identity, and lot numbers that don't trace to specific synthesis batches. The Pew Research Trust and FDA have flagged this independently for the US compounding market.

For UAE researchers running comparison protocols, this matters specifically because compounded GLP-1 product is sometimes compared against retatrutide or branded semaglutide — and the comparison is only valid if both products are what their labels claim. We cover this issue more deeply in GLP-1 microdosing research 2026.

8. What REVIVE LAB UAE actually provides

REVIVE LAB UAE supplies every research peptide with a lot-specific HPLC + MS certificate of analysis. The format includes:

The COA accompanies every parcel and is available on request via WhatsApp before purchase for researchers who want to review the lot-specific documentation. This is the documentation standard the entire peptides UAE catalogue ships with.

9. The summary

References

  1. Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537(7620):347-355. PubMed
  2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed
  3. Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. PubMed
  4. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed
  5. U.S. Food and Drug Administration. Drug Compounding: FDA Concerns Regarding Compounded Versions of GLP-1 Drugs. FDA.gov publication, 2024. FDA